Verteporfin

USP/1711461 - United States Pharmacopeia (USP) Reference Standard

Synonym: (4R,4aS)-rel-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-24H,26H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester; Visudyne; trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester

CAS Number: 129497-78-5
Empirical Formula (Hill Notation): C₄₁H₄₂N₄O₈
Molecular Weight: 718.79
MDL Number: MFCD11982858
Linear Formula: C₄₁H₄₂N₄O₈
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-1711461-200MG	200 mg	$1310.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

API family	verteporfin
application(s)	pharmaceutical (small molecule)
format	neat
grade	pharmaceutical primary standard
InChI	1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h29-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,32-18-,34-17-,35-19-;31-16-,33-18-,34-17-,35-19-/t238-,41+/m00/s1
InChI key	YHNBVDZVUQFVLS-SKJZPIBWSA-N
manufacturer/tradename	USP
SMILES string	CC(C(/C=C1[C@@]2(C)C(/C(N/1)=C/3)=CC=C(C(OC)=O)[C@H]2C(OC)=O)=N/4)=C(CCC(OC)=O)C4=CC5=C(CCC(O)=O)C(C)=C(/C=C6C(C=C)=C(C)C3=N/6)N5.CC(C(/C=C7[C@@]8(C)C(/C(N/7)=C/9)=CC=C(C(OC)=O)[C@H]8C(OC)=O)=N/%10)=C(CCC(O)=O)C%10=CC%11=C(CCC(OC)=O)C(C)=C(/C=C%12C(C=C)

Analysis Note:	These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Biochem/physiol Actions:	Verteporfin is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as macular degeneration. Verteporfin accumulates in abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. Verteporfin localizes predominantly in mitochondria.
General description:	This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia .
Other Notes:	Sales restrictions may apply.

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

UNSPSC

41116107

To Order From a Quote